{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:02:58Z","timestamp":1791975778096,"version":"4.4.0"},"reference-count":6,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":138,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Atopic dermatitis (AD) is a common inflammatory skin disease with multiple clinical manifestations. Among AD phenotypes, psoriasiform AD shows the coexistence of eczematous itching lesions in flexural areas with psoriasiform plaques. The use of anti-interleukin (IL)-4 and anti-IL-13 in psoriasiform AD may lead to therapeutic failure or worsening of manifestations. A recent Delphi consensus proposed Janus kinase inhibitors (JAKi) as a viable alternative, even as a first-line treatment, in patients with different clinical phenotypes of AD, including psoriasiform AD. We performed a retrospective analysis of patients in our dermatology clinic with moderate-to-severe AD who were treated with JAKi. Among 192 patients overall, 21 had psoriasiform AD. We used the Eczema Area and Severity Index (EASI), Pruritus-Numerical Rating Scale and Dermatology Life Quality Index for considering severity scores, and reduction was observed in all 21 patients at week (W) 4, W16 and W24 of treatment. At W16, 81% and 67% achieved EASI-75 and EASI-90, respectively, while at W24 95% of patients achieved EASI-75 and 86% obtained EASI-90. No adverse event led to treatment interruption. This study confirmed the clinical effectiveness of JAKi treatment in adult patients with moderate-to-severe psoriasiform AD, with a good safety profile. These drugs are proposed as the first choice for treating this form of AD, although further studies with larger cohorts are required.<\/jats:p>","DOI":"10.1093\/ced\/llae162","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T09:44:33Z","timestamp":1714729473000},"page":"1232-1234","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy of Janus kinase inhibitors in the treatment of psoriasiform atopic dermatitis"],"prefix":"10.1093","volume":"49","author":[{"given":"Maddalena","family":"Napolitano","sequence":"first","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Foggia","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cataldo","family":"Patruno","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Catanzaro \u2018Magna Graecia\u2019 , Catanzaro ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Gallo","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7997-1784","authenticated-orcid":false,"given":"Nello","family":"Tommasino","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Cecere","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"key":"2025041611020722500_llae162-B1","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/ACI.0000000000000837","article-title":"Clinical phenotypes of adult atopic dermatitis and related therapies","volume":"22","author":"Patruno","year":"2022","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"2025041611020722500_llae162-B2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.18176\/jiaci.0138","article-title":"Atopic dermatitis in adults: a diagnostic challenge","volume":"27","author":"Silvestre Salvador","year":"2017","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2025041611020722500_llae162-B3","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/1346-8138.16764","article-title":"Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: a retrospective study","volume":"50","author":"Napolitano","year":"2023","journal-title":"J Dermatol"},{"key":"2025041611020722500_llae162-B4","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s13555-024-01135-x","article-title":"Management of patients affected by moderate-to-severe atopic dermatitis with JAK inhibitors in real-world clinical practice: an Italian Delphi consensus","volume":"14","author":"Gargiulo","year":"2024","journal-title":"Dermatol Ther (Heidelb"},{"key":"2025041611020722500_llae162-B5","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1159\/000530608","article-title":"Dupilumab-associated psoriasis and psoriasiform manifestations: a scoping review","volume":"239","author":"Su","year":"2023","journal-title":"Dermatology"},{"key":"2025041611020722500_llae162-B6","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/bjd.17779","article-title":"Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition","volume":"181","author":"Napolitano","year":"2019","journal-title":"Br J Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae162\/58504352\/llae162.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/10\/1232\/59183704\/llae162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/10\/1232\/59183704\/llae162.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T15:02:46Z","timestamp":1744815766000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/49\/10\/1232\/7663619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":6,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,5,3]]},"published-print":{"date-parts":[[2024,9,18]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae162","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,5,3]]}}}